SARS-CoV-2 Testing Before International Airline Travel, December 2020 to May 2021

Although there have been several case reports and simulation models of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission associated with air travel, there are limited data to guide testing strategy to minimize the risk of SARS-CoV-2 exposure and transmission onboard commercia...

Descripción completa

Detalles Bibliográficos
Autores principales: Tande, Aaron J., Binnicker, Matthew J., Ting, Henry H., Del Rio, Carlos, Jalil, Lindsey, Brawner, Matthew, Carter, Peter W., Toomey, Kathleen, Shah, Nilay D., Berbari, Elie F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410576/
https://www.ncbi.nlm.nih.gov/pubmed/34736612
http://dx.doi.org/10.1016/j.mayocp.2021.08.019
Descripción
Sumario:Although there have been several case reports and simulation models of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission associated with air travel, there are limited data to guide testing strategy to minimize the risk of SARS-CoV-2 exposure and transmission onboard commercial aircraft. Among 9853 passengers with a negative SARS-CoV-2 polymerase chain reaction test performed within 72 hours of departure from December 2020 through May 2021, five (0.05%) passengers with active SARS-CoV-2 infection were identified with rapid antigen tests and confirmed with rapid molecular test performed before and after an international flight from the United States to Italy. This translates to a case detection rate of 1 per 1970 travelers during a time of high prevalence of active infection in the United States. A negative molecular test for SARS-CoV-2 within 72 hours of international airline departure results in a low probability of active infection identified on antigen testing during commercial airline flight.

Ejemplares similares